XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.

XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.
U
U

UCB

පුවත්

Reuters - දින 3කට පෙර

UCB Raises 2024 Guidance, Completes Sale Of Established Brands

BRIEF-UCB Raises 2024 Guidance, Completes Sale Of Established Brands Nov 5 (Reuters) - Ucb SA UCB.BR : UCB COMPLETES SALE OF ESTABLISHED BRANDS AND UPDATES 2024 FINANCIAL GUIDANCE UPDATE OF 2024 FINANCIAL GUIDANCE, PROJECTING REVENUE NEAR €6 BILLION AND AN ADJUSTED EBITDA MARGIN EXPECTED NOW WITHIN THE UPPER PART OF THE RANGE OF 23.0-24.5% SUCCES
U
Reuters - සති 1කට පෙර

UCB Presents Data On Bepranemab In Early Alzheimer's Disease In Phase 2A Study

BRIEF-UCB Presents Data On Bepranemab In Early Alzheimer's Disease In Phase 2A Study Oct 31 (Reuters) - Ucb SA UCB.BR : UCB PRESENTS ENCOURAGING DATA ON BEPRANEMAB IN EARLY ALZHEIMER’S DISEASE IN PHASE 2A STUDY AT CTAD 2024 RESULTS PROVIDE FIRST EVIDENCE OF BIOLOGICAL AND CLINICAL EFFECT OF A MID-DOMAIN TAU-TARGETING DISEASE-MODIFYING THERAPY IS
U
Reuters - සති 1කට පෙර

Clariant, M6, Ucb

EUROPE RESEARCH ROUNDUP-Clariant, M6, Ucb Oct 30 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Clariant, M6, and Ucb, on Wednesday. HIGHLIGHTS * Adidas AG ADSGn.DE : Deutsche Bank raises target price to EUR 275 from EUR 270 * Clariant AG CLN.S : JP Morgan cuts target price to CHF 14 from CHF 15 * M6 MMTP.PA : JP Morgan cuts target price to EUR 13.1 from EUR 13.7 * Nel ASA NEL.OL : Morgan Stanley cuts to underweight from equal wei
A
A
A
A
B
B
C
C
D
E
E
F
H
H
H
H
K
L
M
R
S
U
V
B
D
Reuters - සති 2කට පෙර

Glencore, Knaus Tabbert, LSE

EUROPE RESEARCH ROUNDUP- Glencore, Knaus Tabbert, LSE Oct 28 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Glencore, Knaus Tabbert and LSE, on Monday. HIGHLIGHTS * Glencore Plc GLEN.L : HSBC raises to buy from hold * Knaus Tabbert AG KTAG.DE : Jefferies cuts to hold from buy * LSE LSEG.L : RBC raises target price to 11,600p from 11,000p * Suzano SUZB3.SA : HSBC raises to buy from hold * Veolia VIE.PA : RBC initiates coverage with
A
B
D
E
E
E
E
F
G
H
H
H
I
K
R
R
R
S
S
U
V
B
E
S
Y
Reuters - මාස 1කට පෙර

EMA Starts Review Of Drugs Containing Finasteride & Dutasteride After Suicidal Ideation Concerns

CORRECTED-BRIEF-EMA Starts Review Of Drugs Containing Finasteride & Dutasteride After Suicidal Ideation Concerns Corrects source of brief to European Medicines Agency, not Merck & Co Oct 4 (Reuters) - European Medicines Agency (EMA): EMA: HAS STARTED A REVIEW OF MEDICINES CONTAINING FINASTERIDE AND DUTASTERIDE FOLLOWING CONCERNS REGARDING SUICIDAL
U
Reuters - මාස 1කට පෙර

UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis

BRIEF-UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis Sept 30 (Reuters) - Ucb SA UCB.BR : ANNOUNCES A HEAD-TO-HEAD STUDY EVALUATING BIMZELX[®]▼(BIMEKIZUMAB) VERSUS SKYRIZI® (RISANKIZUMAB) IN ACTIVE PSORIATIC ARTHRITIS STUDY UNDERSCORES UCB'S BELIEF IN BIMEKIZUMAB WITH TOP-LINE RESULTS EXPECTED IN 2026 Source text:
U
Reuters - මාස 1කට පෙර

UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS

BRIEF-UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS Sept 27 (Reuters) - Ucb SA UCB.BR : ANNOUNCES LATE-BREAKING TWO-YEAR DATA FOR BIMZELX(BIMEKIZUMAB) IN MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA AT EADV 2024 CLINICALLY MEANINGFUL IMPROVEMENTS OBSERVED WITH BIMEKIZUMAB OVER ONE YEAR OF TREATMENT WERE MAINTAINED UP TO TWO YEARS (WE
U
Reuters - මාස 2කට පෙර

Biogen rises after lupus drug meets main goal of late-stage study

BUZZ-Biogen rises after lupus drug meets main goal of late-stage study ** Shares of drugmaker Biogen BIIB.O rise 2.1% to $200 premarket ** Co and partner UCB UCB.BR say their experimental lupus treatment met the main goal of a late-stage trial ** Cos say the drug, dapirolizumab pegol, when given along with other standard of care treatments, showed
B
U
Reuters - මාස 2කට පෙර

UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol

BRIEF-UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol Sept 24 (Reuters) - UCB UCB.BR : UCB AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF DAPIROLIZUMAB PEGOL IN SYSTEMIC LUPUS ERYTHEMATOSUS ARE INITIATING SECOND PHASE 3 STUDY IN 2024 PARTICIPANTS FROM PHOENYCS GO STUDY WILL CONTINUE TO BE FOLLOWED IN A L
B
U
Reuters - මාස 2කට පෙර

Biogen-UCB's lupus drug meets main goal of late-stage trial

CORRECTED-Biogen-UCB's lupus drug meets main goal of late-stage trial Corrects executive's name to Meyers from Myers in paragraphs 5 and 6 By Manas Mishra Sept 24 (Reuters) - Biogen BIIB.O and Belgian partner UCB UCB.BR said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.
A
B
G
U
Reuters - මාස 2කට පෙර

UCB rises on further Bimzelx approvals in the US

BUZZ-UCB rises on further Bimzelx approvals in the US ** Shares in UCB UCB.BR rise 2.2% after the Belgian biopharmaceutical company said the U.S. FDA had approved further indications for its Bimzelx treatment ** Bimzelx gets green light for psoriatic arthritis, nonradiographic axial spondyloarthritis and axial spondyloarthritis, following similar d
U
Reuters - මාස 2කට පෙර

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Asia Cement, McKesson Aug 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Asia Cement (China)'s 0743.HK shareholders have rejected its majority owner's take-private offer, it said. nL4N3KD0SV ** Drug distributor McKesson MCK.N said it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute's business and administrative services unit, Core
N
S
U
M
Reuters - මාස 2කට පෙර

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Aug 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** UCB UCB.BR , a Belgian biopharmaceutical firm, said it would sell its Chinese neurology and allergy business to Singapore-based asset management group CBC and Abu Dhabi sovereign investor Mubadala for $680 million.
N
S
U
Reuters - මාස 2කට පෙර

Belgium's UCB to sell China neurology, allergy business for $680 mln

UPDATE 2-Belgium's UCB to sell China neurology, allergy business for $680 mln Acquisition includes anti-allergy medicines Zyrtec and Xyzal Deal expected to close in fourth quarter UCB to focus on innovation and partnerships Adds context in paragraph 7, advisers in final paragraph By Geert De Clercq and Yantoultra Ngui PARIS/SINGAPORE, Aug 26 (Reuters) - UCB UCB.BR , a Belgian biopharmaceutical firm, said on Monday it would sell its Chinese neurology and allergy business to Singapore-based asset
U
Reuters - මාස 2කට පෙර

Mubadala Co-Invests In UCB's Mature Business In China

BRIEF-Mubadala Co-Invests In UCB's Mature Business In China Aug 26 (Reuters) - MUBADALA INVESTMENT [RIC:RIC:MUDEV.UL]: MUBADALA CO-INVESTS IN UCB'S MATURE BUSINESS IN CHINA TO REINFORCE ITS LONG-TERM COMMITMENT TO ASIAN MARKET CO IN PARTNERSHIP WITH CBC GROUP ACQUIRED 100% OWNERSHIP IN CARVE-OUT OF UCB PHARMA'S MATURE BUSINESS IN CHINA Further comp
U
Reuters - මාස 2කට පෙර

Belgium's UCB sells China neurology and allergy business for $680 million

Belgium's UCB sells China neurology and allergy business for $680 million PARIS, Aug 26 (Reuters) - Belgian biopharmaceutical group UCB said in a statement it had agreed to sell its neurology and allergy business in China to Asian healthcare-dedicated asset management group CBC and Abu Dhabi-based investment company Mubadala for an amount of $680 million.
U
Reuters - මාස 2කට පෙර

UCB To Divest Its Neurology And Allergy Business In China

BRIEF-UCB To Divest Its Neurology And Allergy Business In China Aug 26 (Reuters) - UCB SA UCB.BR : UCB TO DIVEST ITS MATURE NEUROLOGY AND ALLERGY BUSINESS IN CHINA, INCLUDING KEPPRA®, VIMPAT®, NEUPRO®, ZYRTEC® UCB TO DIVEST ITS MATURE NEUROLOGY AND ALLERGY BUSINESS IN CHINA, INCLUDING KEPPRA®, VIMPAT®, NEUPRO®, ZYRTEC®, XYZAL® AND ZHUHAI M
U
Reuters - මාස 3කට පෙර

Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine

BUZZ-Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** JP Morgan raises UCB UCB.BR to "overweight" from "neutral" as it sees the Belgian biotech firm's "superior growth profile" as "significantly" undervalued by the market; cites expected acceleration in Bimzelx growth ** Morgan Stanley downgrades Sonova SOON.S to "underweight" from "equal-weight", flagging the hearing aid maker's EV/EBITA valua
M
S
U
V
V
Reuters - මාස 3කට පෙර

Admiral, UCB SA, Victrex

EUROPE RESEARCH ROUNDUP-Admiral, UCB SA, Victrex Aug 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Admiral, UCB SA and Victrex, on Wednesday. HIGHLIGHTS * Admiral ADML.L : RBC raises target price to 3,550p from 3,400p * Demant A/S DEMANT.CO : Morgan Stanley raises to overweight from underweight * UCB SA UCB.BR : JP Morgan raises to overweight from neutral * Victrex Plc VCTX.L : Jefferies raises to hold from underperform * Watki
A
A
C
H
I
M
N
R
S
S
U
V
V
A
Reuters - මාස 3කට පෙර

AJ Bell, Avon Technologies, Hannover

EUROPE RESEARCH ROUNDUP-AJ Bell, Avon Technologies, Hannover Aug 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AJ Bell, Avon Technologies and Hannover on Tuesday. HIGHLIGHTS * AJ Bell Plc AJBA.L : Morgan Stanley raises target price to 316p from 284p * Avon Technologies Plc AVON.L : Barclays raises target price to 1450p from 1400p * Hannover Re HNRGn.DE : Morgan Stanley raises target price to EUR 254 from EUR 252 * UCB SA UCB.B
A
A
B
B
C
H
H
H
H
K
P
R
R
S
S
T
U
W
P
N

තත්ත්වයන්

ජනප්‍රිය වත්කම්

වියාචනය: XM Group සමාගම් ක්‍රියාත්මක කිරීම පමණක් වන සේවා සපයන අතර වෙබ් අඩවියේ හෝ වෙබ් අඩවිය හරහා ලබා ගත හැකි අන්තර්ගතය බැලීමට සහ/හෝ භාවිත කිරීමට පුද්ගලයෙකුට ඉඩ සලසමින් අපගේ මාර්ගගත වෙළඳ පහසුකම වෙත ප්‍රවේශය ලබා දෙන අතර වෙනස් කිරීමට හෝ පුළුල් කිරීමට අදහස් නොකරයි. එවැනි ප්‍රවේශය සහ භාවිතය සෑම විටම (i) නියමයන් සහ කොන්දේසි, (ii) අවදානම් අනතුරු ඇඟවීම් සහ (iii) සම්පූර්ණ වියාචනයට යටත් වේ. එබැවින් එවැනි අන්තර්ගතයක් සාමාන්‍ය තොරතුරුවලට වඩා වැඩි යමක් සපයා නොමැත. විශේෂයෙන්ම, අපගේ මාර්ගගත වෙළඳ පහසුකමේ අන්තර්ගතය පෙළඹවීමක් හෝ මූල්‍ය වෙළඳපොළවල කිසිදු ගනුදෙනුවක් සිදු කිරීමට ඉදිරිපත් කිරීමක් නොවන බව කරුණාවෙන් සලකන්න. ඕනෑම මූල්‍ය වෙළඳපොළක වෙළඳාම් කිරීම ඔබේ ප්‍රාග්ධනයට සැලකිය යුතු අවදානමක් එක් කරයි.

අපගේ මාර්ගගත වෙළඳ පහසුකමේ ප්‍රකාශිත සියලු කරුණු අධ්‍යාපනික/තොරතුරුමය අරමුණු සඳහා පමණක් අදහස් කෙරෙන අතර මූල්‍ය, ආයෝජන බදු හෝ වෙළඳ උපදෙස් සහ නිර්දේශයන්; හෝ අපගේ වෙළඳ මිල පිළිබඳ වාර්තාවක්; හෝ ඕනෑම මූල්‍ය උපකරණයක ඉදිරිපත් කිරීමක් හෝ ඒ සඳහා පෙළඹවීමක්; හෝ විශේෂ ඉල්ලීමකින් තොරව ඔබ වෙත ලබා දෙන ලද මූල්‍ය ප්‍රවර්ධනයන් ලෙස නොසැලකිය යුතුය.

ඕනෑම තෙවන පාර්ශවීය අන්තර්ගතයක් මෙන්ම XM විසින් සකසන ලද අන්තර්ගතය එනම් අදහස්, පුවත්, පර්යේෂණ, විශ්ලේෂණ, මිල ගණන් සහ වෙනත් තොරතුරු හෝ මෙම වෙබ් අඩවියේ අන්තර්ගත තෙවන පාර්ශවීය වෙබ් අඩවි සඳහා සබැඳි සාමාන්‍ය වෙළඳපොළ විවරණයක් ලෙස "පවතින පරිදි" සපයා ඇති අතර එහි ආයෝජන උපදෙස් ඇතුළත් නොවේ. ඕනෑම අන්තර්ගතයක් ආයෝජන පර්යේෂණයක් ලෙස අර්ථ දක්වා ඇති ප්‍රමාණයට, ආයෝජන පර්යේෂණයේ ස්වාධීනත්වය ප්‍රවර්ධනය කිරීමට නිර්මාණය කර ඇති නෛතික අවශ්‍යතාවලට අනුකූලව අන්තර්ගතය සකසා නොමැති බවත් එලෙස අරමුණු කර නොමැති බවත් ඔබ සලකා පිළිගත යුතු අතර එබැවින් එය අදාළ නීති සහ රෙගුලාසි යටතේ අලෙවිකරණ සන්නිවේදනයක් ලෙස සලකනු ලැබේ. ඉහත සඳහන් තොරතුරු සලකා මෙතනින් ප්‍රවේශ විය හැකි, ස්වාධීන නොවන ආයෝජන පර්යේෂණ සහ අවදානම් අනතුරු ඇඟවීම පිළිබඳ අපගේ දැනුම්දීම ඔබ කියවා තේරුම් ගෙන ඇති බව සහතික කර ගන්න.

අවදානම් අනතුරු ඇඟවීම: ඔබේ ප්‍රාග්ධනය අවදානමේ පවතී. උත්තෝලිත (ලෙවරේජ්) නිෂ්පාදන සෑම දෙනාටම සුදුසු නොවිය හැකිය. කරුණාකර අපගේ අවදානම් අනාවරණය සලකා බලන්න.